Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Feb 13, 2021KEYTRUDA Plus LENVIMA Significantly Reduced Risk of Disease Progression or Death by 61% Versus Sunitinib, With a Median PFS of Nearly Two Years Versus Nine Months for SunitinibKENILWORTH, N.J., and WOODCLIFF LAKE, N.J., Feb. 13, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced the first presentation of new...
Jan 27, 2021Data include the first presentation of results from the pivotal Phase 3 CLEAR study (KEYNOTE-581/Study 307) evaluating KEYTRUDA® (pembrolizumab) plus LENVIMA and LENVIMA plus everolimusEisai will present four abstracts at the virtual Genitourinary Cancers Symposium 2021 (#GU21) from February 11-13, 2021. These investigational data include a late-breaking oral presentation from...
Jan 11, 2021Eisai will present five abstracts across four tumor types at the Gastrointestinal Cancers Symposium (#GI21), which is being held virtually from January 15-17, 2021. Investigational data on the...
-
Dec 16, 2020First Overall Survival Analysis for KEYTRUDA Plus LENVIMA Combination in a Phase 3 Study in Advanced Endometrial Cancer
KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., Dec. 16, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the pivotal Phase 3...
-
Dec 8, 2020Latest Initiative of #ThisIsMBC "Perseverance" to be Unveiled at the 2020 Virtual San Antonio Breast Cancer Symposium
Eisai Inc. and METAvivor today announced the launch of Perseverance, a new initiative of the #ThisIsMBC campaign. Perseverance showcases imagery of a diverse group of 12 participants capturing the...
- Nov 20, 2020Results support 24 mg as the starting dose for LENVIMA in patients with radioactive iodine-refractory differentiated thyroid cancer
Eisai announced results from Study 211 evaluating the safety and efficacy of LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, at two starting doses:...
-
Nov 19, 2020Key findings reinforce safety and efficacy and dosing strategies of LENVIMA
Eisai announced today the presentation of three abstracts including investigational data in thyroid cancer and osteosarcoma at the European Society for Medical Oncology (ESMO) Asia Virtual...
Nov 10, 2020LENVIMA Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus SunitinibKENILWORTH, N.J., and WOODCLIFF LAKE, N.J., November 10, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new investigational data...
- Nov 7, 2020Study 218 compares 18 mg and 14 mg starting doses of LENVIMA plus 5 mg everolimus in patients with clear-cell RCC following prior anti-angiogenic therapy, with prior anti-PD-1/PD-L1 therapy permitted
Eisai announced results from Study 218, a Phase 2 trial comparing the safety and efficacy of two different starting doses (18 mg versus 14 mg once daily) of LENVIMA, an orally available multiple...
- Nov 5, 2020Data includes an oral presentation on results from a Phase 2 trial evaluating starting doses of LENVIMA in combination with everolimus (LEN+EVE)
Eisai will present seven abstracts at the International Kidney Cancer Symposium (IKCS) 2020 from November 6-7, 2020. New investigational data from Study 218, a Phase 2 trial evaluating the safety...